Key result
NOACs are recommended for stroke prevention in adults with simple congenital heart disease, but there is less certainty regarding their safety in patients with moderate or complex lesions.
Why the study?
Adults with congenital heart disease face elevated arrhythmia and stroke risks, but certainty is lacking regarding the safety of NOACs in those with moderate or complex lesions.
What is the evidence for stroke risk and the use of anticoagulants and interventional therapies in adult patients with congenital heart disease?
What is the evidence for stroke risk and the use of anticoagulants and interventional therapies in adult patients with congenital heart disease?
Answers are grounded in this paper and cite their sources.
This narrative review highlights the need for tailored stroke risk assessment and careful consideration of NOAC safety in adults with moderate or complex congenital heart disease.
With improvements in treatment of congenital heart disease more paediatric patients are surviving with palliative or corrective interventions during childhood, thus becoming adults with congenital heart disease (ACHD). Overall, the ACHD population is at a higher risk of arrhythmias and stroke. The abnormal structure and function of their corrected hearts suggests that in addition to established stroke risk factors, such as prior stroke or older age, additional stroke risk factors need to be considered to determine the risk and establish the indication for oral anticoagulation (OAC) in ACHD patients. In structurally normal hearts non-vitamin-K oral anticoagulants (NOACs) offer at least equal stroke prevention with a better safety profile compared to vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) or pulmonary embolism. Current guidelines recommend NOACs in ACHD patients with simple lesions and indication for OAC, while there is less certainty about their safety in ACHD patients with moderate or complex congenital heart disease such as patients with transposition of the great arteries (TGA) after atrial switch operation (Senning or Mustard operation), Fontan circulation or congenital corrected transposition of the great arteries (ccTGA). This review summarises the available evidence characterising stroke risk in patients with ACHD and the use of anticoagulants and interventional therapies to reduce that risk.
No takes yet. Share an insight, caveat, or question.
Sinning et al. (2021) conducted a review in Adults with congenital heart disease (ACHD). Oral anticoagulation (NOACs vs VKA) was evaluated. NOACs are recommended for stroke prevention in adults with simple congenital heart disease, but there is less certainty regarding their safety in patients with moderate or complex lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: